Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has provided an update.
Daito Pharmaceutical Co., Ltd. announced a strategic absorption-type merger with its wholly owned subsidiary, Daiwa Pharmaceutical Co., Ltd., effective June 1, 2025. This merger aims to enhance operational efficiency and quality in product manufacturing, supporting the company’s commitment to a stable pharmaceutical supply.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. operates within the pharmaceutical industry, focusing on the manufacture and supply of active pharmaceutical ingredients and drug products. The company emphasizes streamlining operations and enhancing cooperation with its subsidiary Daiwa Pharmaceutical Co., Ltd.
YTD Price Performance: -3.83%
Average Trading Volume: 24,028
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen30.84B
For an in-depth examination of 4577 stock, go to TipRanks’ Stock Analysis page.